Tag Archives: President Trump

Zynerba sinks twice as cannabis trials flop; strike three looms, so where’s the Ouija board?

The News: Zynerba Pharmaceuticals Inc. (ZYNE) lost more than half its value last week to $7.03 after the drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage… Read more »



GOP’s latest health bill looking more like a white flag on Obamacare repeal promise; McCain’s return won’t save McConnell’s maneuvers.

The News: Shortly after Senate Majority Leader Mitch McConnell unveiled a revised bill last Thursday to overhaul the US healthcare system, lawmakers undecided about the proposed changes to Medicaid gathered together… Read more »



GOP Senate bill ignites massive rally in healthcare stocks; remember the dot-com era?

US healthcare stocks posted sharp gains last week, with pharma, hospitals and insurers climbing after Senate Republicans released a draft bill to scrap Obamacare, while a recent explosion in biotech… Read more »



Rather than imploding per Pres. Trump, Obamacare actually stabilizing per S&P report; who to believe

The News: The Obamacare markets are stabilizing for insurers, said a report released by Standard & Poor’s Financial Services LLC (NYC), but that could change if lawmakers choose to alter… Read more »



Stock markets closed Friday prior to collapse of Trumpcare; health sector’s biggest winners & losers as of March 24, 2017

Republican bickering has led to the biggest rout yet for President Trump’s early administration. As I expected, the GOP plan to gut the Affordable Care Act collapsed Friday (March 24,… Read more »



GOP can’t handle the truth: millions to lose coverage under Trumpcare

Steve’s Take: Remember President Trump’s pre- and post-election promise, no, it sounded more like a guarantee, of “insurance for everybody?” Then last week, the Trump-backed House bill, when finally unveiled… Read more »



Trump tweet on drug prices sinks pharma shares; what’s next, doctors’ wages? Not.

Steve’s Take: President Trump’s morning ritual continues to enthrall millions, but occasionally causes Wall Street analysts covering the pharma industry to reach for their bottle of Maalox. After House Republicans… Read more »



After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »



Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »



Trumpcare slowly imploding; perhaps morphing into Obamacare 2.0?

Steve’s Take: Six years after its passage, the Affordable Care Act has demonstrated it’s far from perfect. But replacing such an immense, complicated law on an accelerated schedule is presenting… Read more »